SCHEMBL864345

SCHEMBL864345

CC(C)(C)OC(=O)NNC(=S)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.55
NR4A2 P43354 2/20 0.54
NR4A1 P22736 1/20 0.54
NR4A3 Q92570 1/20 0.54
PARP10 Q53GL7 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
HDAC1 Q13547 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
SRD5A2 P31213 1/20 0.50
HDAC3 O15379 1/20 0.49
HDAC2 Q92769 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
ADRB3 P13945 1/20 0.48
PPARG P37231 1/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL864308 0.87 HDAC1 (0.61) MAOBNR4A2NR4A1NR4A3PARP10
SCHEMBL12473429 0.83 NR4A1 (0.64) MAOBNR4A2NR4A1NR4A3PARP10
SCHEMBL2009888 0.80 HDAC1 (0.55) MAOBNR4A2NR4A1NR4A3PARP10
SCHEMBL22138858 0.80 MAOB (0.55) MAOBNR4A2NR4A1NR4A3PARP10
SCHEMBL6779534 0.80 MAOB (0.65) MAOBNR4A2NR4A1NR4A3PARP10
SCHEMBL6243210 0.80 HDAC1 (0.54) MAOBSMN1; SMN2HDAC1NPC1RAB9A
SCHEMBL2987817 0.79 RAB9A (0.74) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL749687 0.79 HDAC1 (0.60) MAOBNR4A2NR4A1NR4A3SMN1; SMN2
SCHEMBL17825515 0.79 TP53 (0.53) MAPTKMT2APLA2G4BHTT
SCHEMBL596575 0.78 HDAC1 (0.67) MAOBSMN1; SMN2HDAC1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621278-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2013-08-07 EP disclosed
US-8476302-B2 α-ketoamide derivatives useful endothelial lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-07-02 US disclosed
WO-2012047580-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-04-12 WO disclosed
US-20120077847-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077847-A1 ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS LIPG, LIPA, LIPE MAOB 1021/4885NR4A2 1563/4885NR4A1 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.